Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Related Citations for PubMed (Select 24555168)

1.

Pharmaceutical company perspectives on current safety risk communications in Japan.

Urushihara H, Kobashi G, Masuda H, Taneichi S, Yamamoto M, Nakayama T, Kawakami K, Matsuda T, Ohta K, Sugimori H.

Springerplus. 2014 Jan 24;3:51. doi: 10.1186/2193-1801-3-51. eCollection 2014.

2.

Risk Communication and the Pharmaceutical Industry: what is the reality?

Edwards B, Chakraborty S.

Drug Saf. 2012 Nov 1;35(11):1027-40. doi: 10.2165/11635220-000000000-00000.

PMID:
23061779
3.
5.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

6.

Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop.

Minagawa T, Nakano K, Furuta S, Iwasa T, Takekawa K, Minato K, Koga T, Sato T, Kawashima K, Kurahashi Y, Onodera H, Naito S, Nakamura K.

J Toxicol Sci. 2012;37(4):667-73. Review.

7.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

8.

Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.

[No authors listed]

BioDrugs. 2003;17(1):69-72.

PMID:
12534322
9.
10.

[Preventive measures against tuberculosis in working facilities and companies].

Suzuki K, Satou K.

Kekkaku. 2007 Mar;82(3):201-16. Japanese.

PMID:
17444125
11.

Factors associated with spontaneous reporting of adverse drug reactions in Japan.

Yamada T, Watanabe Y, Kusama M, Sugiyama Y, Ono S.

Pharmacoepidemiol Drug Saf. 2013 May;22(5):468-76. doi: 10.1002/pds.3378. Epub 2012 Nov 21.

PMID:
23172714
12.

Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety.

Blum AB, Shea S, Czeisler CA, Landrigan CP, Leape L.

Nat Sci Sleep. 2011 Jun 24;3:47-85. doi: 10.2147/NSS.S19649. Print 2011.

13.

Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.

Swain E, Morgan S, Brewster W, Kauser S.

Pharmacoepidemiol Drug Saf. 2010 Mar;19(3):232-7. doi: 10.1002/pds.1898.

PMID:
20033909
14.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
15.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
16.

Allergic reactions to Japanese encephalitis vaccine.

Plesner AM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. Review. Erratum in: Immunol Allergy Clin North Am. 2004 May;24(2):335.

PMID:
14753386
17.

The future of risk communication and the role of the pharmaceutical industry.

Chakraborty S, Bouder F.

Curr Drug Saf. 2013 Feb;8(1):4-10.

PMID:
23656442
18.

Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.

Mori Y, Nishikawa Y, Iizuka T, Zenimura N, Matsumoto T, Hiramatsu K, Komiya M.

Drugs R D. 2011;11(2):171-90. doi: 10.2165/11592450-000000000-00000.

19.
20.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk